Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company that creates medicines for patients. Its programs target the Tyrosine Kinase 2 (TYK2) pseudokinase domain. The company is developing TYK2 inhibitors, including a brain-penetrant candidate for treating multiple sclerosis and neurodegenerative diseases with neuroinflammation, as well as a topical candidate for immune-mediated dermatologic conditions.